Empire Life Investments Inc. decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 3.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,758 shares of the medical instruments supplier’s stock after selling 2,609 shares during the quarter. Empire Life Investments Inc.’s holdings in Becton, Dickinson and were worth $13,669,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BDX. Family Firm Inc. lifted its holdings in shares of Becton, Dickinson and by 0.5% in the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after purchasing an additional 6 shares during the last quarter. Northwest Quadrant Wealth Management LLC lifted its holdings in shares of Becton, Dickinson and by 0.4% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after purchasing an additional 6 shares during the last quarter. Wellington Shields & Co. LLC lifted its holdings in shares of Becton, Dickinson and by 0.3% in the 2nd quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock worth $496,000 after purchasing an additional 7 shares during the last quarter. Northstar Group Inc. lifted its holdings in shares of Becton, Dickinson and by 0.3% in the 2nd quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock worth $584,000 after purchasing an additional 9 shares during the last quarter. Finally, NBT Bank N A NY lifted its holdings in shares of Becton, Dickinson and by 0.3% in the 2nd quarter. NBT Bank N A NY now owns 3,351 shares of the medical instruments supplier’s stock worth $654,000 after purchasing an additional 10 shares during the last quarter. Institutional investors own 88.46% of the company’s stock.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.40% of the stock is owned by insiders.

Several analysts recently issued reports on BDX shares. Royal Bank Of Canada reissued a “hold” rating and issued a $210.00 price target on shares of Becton, Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research downgraded Becton, Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, October 9th. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 price target on shares of Becton, Dickinson and in a report on Friday, November 3rd. Morgan Stanley raised their price target on Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Finally, Wells Fargo & Company reissued a “positive” rating and issued a $235.00 price target (up previously from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Becton, Dickinson and has a consensus rating of “Buy” and a consensus price target of $217.08.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at $217.81 on Friday. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. The firm has a market capitalization of $49,660.00, a price-to-earnings ratio of 23.07, a price-to-earnings-growth ratio of 1.71 and a beta of 1.06. Becton, Dickinson and Company has a 12 month low of $161.50 and a 12 month high of $229.68.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating the consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.12 EPS. equities research analysts expect that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be paid a dividend of $0.75 per share. The ex-dividend date is Thursday, December 7th. This represents a $3.00 annualized dividend and a yield of 1.38%. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. Becton, Dickinson and’s payout ratio is presently 62.80%.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/08/empire-life-investments-inc-decreases-stake-in-becton-dickinson-and-company-bdx.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.